» Articles » PMID: 26079300

Time-varying Effect and Long-term Survival Analysis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Overview
Journal Br J Cancer
Specialty Oncology
Date 2015 Jun 17
PMID 26079300
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recent studies have indicated the prognostic value of tumour subtype and pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). However these results were reported after a short follow-up and using a standard Cox model which could be unsatisfactory for time-dependent factors. In the present study, we identified the prognostic factors for long-term outcome after NAC, considering that they could have an inconstant impact over time.

Methods: Prognostic factors from 956 consecutive breast cancer patients treated with NAC were identified and associated with long-term outcomes. We estimated survival by a time function multivariate Cox model regression and stratified by follow-up length.

Results: The prognostic value of tumour histological grade and hormone receptors status varied as distant recurrence-free interval (DRFI) increased. The multivariate analysis identified the following significant prognostic factors: tumour size, N stage, clinical and pathological response to NAC, hormone receptors (HR) status and histological tumour grade. The 'prognostic benefit' of low-grade and positive-HR status decreased over the years. Thus, in the early years after cancer diagnosis, the hazard ratio of distant recurrences in patients with positive-HR status increased from 0.26 (95% CI 0.1-0.4) at 6 months to 2.2 (95% CI 1.3-3.7) at 120 months. The histological tumour grade followed a similar trend. The hazard ratio of grade III patients compared with grade I was 1.83 (95% CI 1.1-2.8) at 36 months and diminished over time to 0.70 (95% CI 0.4-1.3) at 120 months. This indicates that the risk of recurrence for positive-HR patients was 74% lower at 6 months compared with the negative-hormone receptor group, but 30% higher at 5 years and more than double at 10 years. High-grade tumours presented a risk of 83% in the earlier years decreasing to 30% at 10 years versus the low-grade group.

Conclusion: From the present study, we conclude the importance of identifying time-dependent prognostic factors. Distant recurrence-free interval within women who receive NAC are influenced by achieving pCR and breast cancer subtype. Tumours with more aggressive biology have poorer survival during the first 5 years, but if they exceed this point their prognostic impact is no longer significant. Conversely, positive-HR patients remain at risk for distant recurrence for many years.

Citing Articles

Health-Related Quality of Life and Disease Acceptance Among Women with Breast Cancer Pre- and Post-Neoadjuvant Chemotherapy.

Konieczny M, Sawicka J, Gaska I, Kaczmar E, Babuska-Roczniak M, Badziul D Cancers (Basel). 2025; 17(3).

PMID: 39941864 PMC: 11816349. DOI: 10.3390/cancers17030497.


surtvep: An R package for estimating time-varying effects.

Luo L, Wu W, Taylor J, Kang J, Kleinsasser M, He K J Open Source Softw. 2024; 9(98).

PMID: 39717690 PMC: 11664633. DOI: 10.21105/joss.05688.


Time-varying effect in older patients with early-stage breast cancer: a model considering the competing risks based on a time scale.

Yu Z, Geng X, Li Z, Zhang C, Hou Y, Zhou D Front Oncol. 2024; 14:1352111.

PMID: 39015489 PMC: 11249566. DOI: 10.3389/fonc.2024.1352111.


Time-varying associations of patient and tumor characteristics with cancer survival: an analysis of SEER data across 14 cancer sites, 2004-2017.

Roberts E, Luo L, Mondul A, Banerjee M, Veenstra C, Mariotto A Cancer Causes Control. 2024; 35(10):1393-1405.

PMID: 38811511 PMC: 11461102. DOI: 10.1007/s10552-024-01888-y.


Using information criteria to select smoothing parameters when analyzing survival data with time-varying coefficient hazard models.

Luo L, He K, Wu W, Taylor J Stat Methods Med Res. 2023; 32(9):1664-1679.

PMID: 37408385 PMC: 10868332. DOI: 10.1177/09622802231181471.


References
1.
von Minckwitz G, Untch M, Blohmer J, Costa S, Eidtmann H, Fasching P . Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30(15):1796-804. DOI: 10.1200/JCO.2011.38.8595. View

2.
. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

3.
Soerjomataram I, Louwman M, Ribot J, Roukema J, Coebergh J . An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2007; 107(3):309-30. PMC: 2217620. DOI: 10.1007/s10549-007-9556-1. View

4.
Lee J, Kim S, Park H, Lee J, Park S, Park B . The impact of local and regional recurrence on distant metastasis and survival in patients treated with breast conservation therapy. J Breast Cancer. 2011; 14(3):191-7. PMC: 3200514. DOI: 10.4048/jbc.2011.14.3.191. View

5.
Balaton A, Coindre J, Collin F, Ettore F, Fiche M, Jacquemier J . [Recommendations for the immunohistochemical evaluation of hormone receptors on paraffin sections of breast cancer. Study Group on Hormone Receptors using Immunohistochemistry FNCLCC/AFAQAP. National Federation of Centres to Combat Cancer/French...]. Ann Pathol. 1996; 16(2):144-8. View